The platform for the medical research community MedNous wrote an article about our CervISA study:
Synthetic long peptides deliver response
A therapeutic cancer vaccine consisting of synthetic long peptides has delivered a meaningful survival benefit for cervical cancer patients when administered in combination with standard-of-care chemotherapy.
Sunday 22 March 2020
A therapeutic cancer vaccine consisting of synthetic long peptides has delivered a meaningful survival benefit for cervical cancer patients when administered in combination with standard-of-care chemotherapy. The Phase 2 trial showed that the vaccine and carboplatin/paclitaxel chemotherapy were associated with prolonged survival.
The study was led by Cornelis Melief, chief scientific officer of ISA Pharmaceuticals BV, and published in the 18 March edition of Science Translational Medicine. The vaccine, ISA101, consists of 13 synthetic long peptides derived from the E6 and E7 oncogenic proteins of the HPV16 virus. According to the company, this strain is responsible for 50% of human cervical cancers and cervical intra-epithelial neoplasias and more than 85% of HPV-positive head and neck cancers, anal cancers and premalignant HPV-induced anal lesions.
Seventy-seven patients with late-stage cervical cancer were treated in the trial, which was an open-label study conducted in multiple hospitals in Belgium and the Netherlands. Patients received the vaccine at two weeks after the second, third and fourth cycles of chemotherapy. Tumour regressions were observed in 43% of 72 evaluable patients. Additionally, 11 of the 14 patients still alive at the end of the study displayed a strong vaccine induced response. Dr Melief said the study demonstrated the benefit of the vaccine-chemotherapy approach and may be applicable across many cancer types. For cancers other than cervical cancer, the vaccine would need to be adjusted to include the relevant neoantigens. ISA Pharmaceuticals announced the study results on 19 March 2020.